NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NATURETIN-2.5 (bendroflumethiazide) by Bristol Myers Squibb is clinical pharmacology nadolol nadolol is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure. First approved in 1959.
Drug data last refreshed 6h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Nadolol Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood…
Worked on NATURETIN-2.5 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.